Periodic Reporting for period 2 - EuroNanoMed III (ERA-NET ON NANOMEDICINE)
Reporting period: 2017-11-01 to 2022-10-31
ERA-NET EuroNanoMed: an efficient tool to foster the competitiveness of European nanomedicine actors through the support of transnational collaborative and multidisciplinary research projects.
The ERA-NET scheme, created by the European Commission (EC), serves as a powerful instrument for gathering the main funding organisations from Member States, Associated Countries, regions and other countries for pooling resources and fund transnational research projects on Nanomedicine. Pure nationally funded programmes often face difficulties to successfully translate fundamental research in first clinical stages, as in many member states there are too few players in the specific domain of nanomedicine. Therefore, the main goal of EuroNanoMed (ENM) partners is to foster the competitiveness of European nanomedicine actors through the support of transnational collaborative and multidisciplinary research projects and establishing collaborations with key initiatives in the field. EuroNanoMed has proven to be a solid, competent and internationally recognized consortium, which has established strong collaborations with other actors in the European landscape, including ETPN
EuroNanoMed III was built on the foundations of two other ERA-NETs. During the period 2009-2015, the ERANETs ENM I & II (2009-2011 and 2012-2016) successfully launched 7 joint calls for proposals (the 7th is currently open) in line with the strategic priorities of the European Technology Platform on Nanomedicine (ETPN), which allowed ENM to fund 51 transnational research projects involving 269 partners from 25 ountries/regions participating in the calls, with about € 45,5 million funding from the ENM funding agencies (see section 1.3 for details).
The ERA-NET scheme, created by the European Commission (EC), serves as a powerful instrument for gathering the main funding organisations from Member States, Associated Countries, regions and other countries for pooling resources and fund transnational research projects on Nanomedicine. Pure nationally funded programmes often face difficulties to successfully translate fundamental research in first clinical stages, as in many member states there are too few players in the specific domain of nanomedicine. Therefore, the main goal of EuroNanoMed (ENM) partners is to foster the competitiveness of European nanomedicine actors through the support of transnational collaborative and multidisciplinary research projects and establishing collaborations with key initiatives in the field. EuroNanoMed has proven to be a solid, competent and internationally recognized consortium, which has established strong collaborations with other actors in the European landscape, including ETPN
EuroNanoMed III was built on the foundations of two other ERA-NETs. During the period 2009-2015, the ERANETs ENM I & II (2009-2011 and 2012-2016) successfully launched 7 joint calls for proposals (the 7th is currently open) in line with the strategic priorities of the European Technology Platform on Nanomedicine (ETPN), which allowed ENM to fund 51 transnational research projects involving 269 partners from 25 ountries/regions participating in the calls, with about € 45,5 million funding from the ENM funding agencies (see section 1.3 for details).
EuroNanoMed III has funded 61 projects through its 5 JTCs (2016-2022). Groups from 23 countries have participated in their execution. With the aims to support translational research projects that combine innovative approaches in the field of nanomedicine and; to encourage and enable transnational collaboration between public and private Partners from academia and clinical, the programme allocated 50.47 M € in Projects covering Diagnostics, Regenerative medicine and, in a higher number, Targeted delivery systems.
Regarding the technology readiness level of those funded projects, the majority of them end in *TRL4 and TRL5. During this period, ENMIII has successfully funded Projects from a wide range of technical areas such as analytical tools, nanoimaging, nanomaterials and nanodevices, novel therapeutics and drug delivery systems, clinical, regulatory and toxicological issues. The medical domains have changed across the timeline. Most of the Projects are related with oncology/cancer, neurology and infectious diseases but we can also mention projects on dermatology, ophtalmology and/or metabolism.
Regarding the technology readiness level of those funded projects, the majority of them end in *TRL4 and TRL5. During this period, ENMIII has successfully funded Projects from a wide range of technical areas such as analytical tools, nanoimaging, nanomaterials and nanodevices, novel therapeutics and drug delivery systems, clinical, regulatory and toxicological issues. The medical domains have changed across the timeline. Most of the Projects are related with oncology/cancer, neurology and infectious diseases but we can also mention projects on dermatology, ophtalmology and/or metabolism.
Nanotechnology applications for health care are having a tremendous impact on European’s industrial sector and international markets and this impact has even increased from the launch of ENM III. Nevertheless, more efforts and partnerships between EU countries to achieve better results, treatments and diagnostic tools are needed and therefore the continuation of the funding in the field of nanomedicine is needed in the European Partnership that was launched November 2022 called ERA4Health which will assure European funding for the field of nanomedicine. Thanks to the joint implementation of a transnational funding initiative within ENM III a tremendous impact in the advance of new therapies using nanomedicine methods has been observed.
In a nutshell, ENMIII provided a clear perspective for stakeholders in Nanotechnology for Health Care to find tailor-made support at the level of information, communication, networking and funding that fits their needs best. It is expected that ENMIII results will help to contribute to keep Europe’s highly competitive position in Nanomedicine worldwide.
In a nutshell, ENMIII provided a clear perspective for stakeholders in Nanotechnology for Health Care to find tailor-made support at the level of information, communication, networking and funding that fits their needs best. It is expected that ENMIII results will help to contribute to keep Europe’s highly competitive position in Nanomedicine worldwide.